FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 385 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT... January 10, 2024 That Cancer Conversation is back! April 19, 2023 Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers October 19, 2021 The director’s cut: How Dr Catherine Elliott sees the future of... November 2, 2021 Load more HOT NEWS Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer Foodie Friday: It’s Berry Season! Philanthropist Simon Collins: “I realised I could make a difference by... Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of...
